Helmholtz Hybrid GLP‑1 Drug Slashes Mouse Weight
SkimNews Take
By leveraging existing receptor pathways to deliver a secondary therapeutic, this drug design could enable more targeted and efficient delivery of diverse payloads, reducing systemic exposure and off-target effects across various conditions.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Prof Timo D. Müller and his team at Helmholtz Munich created a hybrid obesity drug that links a GLP‑1/GIP incretin moiety with the pan‑PPAR agonist lanifibranor.
- Mice given the hybrid drug ate less, lost more weight, and showed better blood‑glucose control than those receiving standard GLP‑1 treatments.
- GLP‑1/GIP receptors mediate the drug’s entry into cells, allowing the lanifibranor cargo to act locally and permit lower dosing.
- Nature published the preclinical study.
Why it matters: Patients with obesity and type 2 diabetes gain a lower‑dose therapy that reduces side‑effects, while drug makers acquire a novel, cheaper product that reshapes the multi‑billion‑dollar GLP‑1 market.
